Latest Videos Archives

ERAS Pathways in Radical Cystectomy

Posted by Jeffrey M. Holzbeierlein, MD | May 2020

Jeffrey M. Holzbeierlein, MD, Director of the Division of Urologic Oncology at the University of Kansas Hospital and Director of Clinical Research for the Urology Department at KUMC, discusses the variability associated with ERAS pathways & the impact of utilizing this methodology following cystectomy. He goes on to discuss how to optimize cystectomy through ERAS-based prehab, pre-operative, intraoperative, and post-operative pathways and presents data that demonstrates how these pathways may improve patient outcomes. Finally, Dr. Holzbeierlein discusses the preliminary results of a University of Kansas research program that adapted interactive, iPad-based cystectomy tutorials to understand if personalized education platforms could help improve perioperative care and outcomes within this patient population.

Radiation, Immunotherapy + the Abscopal Effect

Posted by David Utz | May 2020

Radiation, Immunotherapy + the Abscopal Effect This interview, “Radiation, Immunotherapy +...

What Does Suspicion for Prostate Cancer Mean, and What Metric Defines Prostate Cancer Risk?

Posted by Jelle Barentsz, MD, PhD | May 2020

E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology, interviews Jelle Barentsz, MD, PhD, Professor of Radiology at the University in Nijmegen in the Netherlands, about prostate cancer suspicions and which metrics define prostate cancer risk. Dr. Barentsz discusses the steps that must be taken if there is a suspicion of prostate cancer and emphasizes the importance that MRIs and molecular markers play in this. He notes that in an optimal world with a perfect MRI a molecular marker test is often unnecessary, but that sometimes we do not have perfect MRIs, and in these cases, molecular marker tests like SelectMDX are good tests to use. However, MRIs offer more information about potential cancer and are also better at excluding more significant cancers than molecular marker tests. Dr. Crawford and Dr. Barentsz come to the conclusion that which is better or necessary often depends on the country the patient resides in.

Surgery for Recurrent Prostate Cancer

Posted by David Utz | May 2020

Surgery for Recurrent Prostate Cancer This interview, “Surgery for Recurrent Prostate...

Management of High-Grade T1 Bladder Cancer

Posted by Jeffrey M. Holzbeierlein, MD | May 2020

Jeffrey M. Holzbeierlein, MD, Director of the Division of Urologic Oncology at the University of Kansas Hospital and Director of Clinical Research for the Urology Department at KUMC, talks about how to manage high-grade T1 bladder cancer (HGT1BC). He discusses 5-year progression rates of HGT1BC, pathological substratification of the disease, and risk calculators to estimate patient progression. Dr. Holzbeierlein concludes by discussing enhanced cystoscopy, the value of re-resection, and the importance of bacillus Calmette-Guerin (BCG) maintenance in HGT1BC.